Table 2.
Treatment-related adverse events in 32 patients
| Treatment-related events | Any grade | Grade 1–2 | Grade 3 | Grade 4 |
| Anemia | 19 (59) | 18 (56) | 1 (3) | – |
| Neutropenia | 26 (81) | 19 (59) | 6 (19) | 1 (3) |
| Thrombocytopenia | 20 (62) | 2 (6) | 7 (22) | 11 (34) |
| Nausea | 29 (91) | 29 (91) | – | – |
| Vomit | 4 (13) | 4 (13) | – | – |
| Constipation | 7 (22) | 7 (22) | ||
| Fatigue | 21 (66) | 21 (66) | – | – |
| Rash | 1 (3) | 1 (3) | – | – |
| Fever | 11 (34) | 11 (34) | – | – |
| Elevated alanine aminotransferase | 9 (28) | 8 (25) | 1 (3) | – |
| Elevated aspartate aminotransferase | 9 (38) | 8 (25) | – | 1 (3) |
| Elevated amylase | 1 (3) | 1 (3) | – | – |
| Elevated lipase | 2 (6) | 1 (3) | 1 (3) | – |
| Hyponatremia | 1 (3) | – | – | 1 (3) |
| Peripheral neuropathy | 2 (6) | 2 (6) | – | – |
| Hypertension | 2 (6) | – | 2 (6) | – |
Data are n (%), unless otherwise specified.
No patients had fatal treatment-related adverse events.